US FDA panel backs Gloucester's Istodax for cutaneous T-cell lymphoma
03 September 2009
Sue Sutter
The US
FDA's oncologic drugs advisory panel has endorsed Gloucester Pharmaceuticals' Istodax (romidepsin) for cutaneous T-cell lymphoma (CTCL). The panel voted 10 to zero, with one abstention, that the results of two single-arm studies represented a favourable risk/benefit profile for...
Please Login to read the full article.